NCT07754929Recruiting
E-Mergir: A Digital Psychosexual Intervention for the Promotion of Mental and Sexual Health of Prostate Cancer Survivors
E-Mergir: a Randomized Controlled Trial to Test the Efficacy of a Digital Psychosexual Intervention for the Promotion of Mental and Sexual Health of Prostate Cancer Survivors
Source: ClinicalTrials.gov · Last updated 10 Aug 2026
Brief summary (registry, in English)
Prostate cancer (PCa) survivors frequently experience enduring psychosexual challenges following treatment, including sexual dysfunction, emotional distress, and reduced quality of life. Despite these difficulties, access to tailored support remains limited, highlighting the need for scalable and accessible alternatives such as digital interventions. This study presents the protocol for a randomized controlled trial (RCT) evaluating the effectiveness of E-Mergir, a digital psychosexual intervention developed for PCa survivors. Grounded in cognitive behavioral therapy (CBT) and mindfulness strategies, the intervention aims to enhance both sexual and mental well-being. The trial employs a wait-list control design with randomized allocation. Participants will complete assessments at baseline, post-intervention, and follow-up, using validated measures related to sexual outcomes (sexual satisfaction, pleasure, function, distress, and beliefs) and mental health outcomes (quality of life, anxiety, depression, mindfulness, relationship satisfaction, and automatic thoughts). The study aims to determine whether E-Mergir is an effective digital intervention for improving psychosexual outcomes in PCa survivors, compared to a wait-list control group. It also aims to examine treatment predictors to illustrate the mechanisms through which improvements in mental and sexual health are achieved. If effective, E-Mergir could address a critical gap in supportive care for PCa survivors and serve as a model for culturally tailored digital psychosexual interventions globally.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 106 (estimated)
- First submitted
- 18 Mar 2026
- Start date
- 1 Jul 2026
- Primary completion date
- 1 Jan 2027
- Lead sponsor
- Universidade do Porto
- Diseases
- Prostate cancer
- NCT number
- NCT07754929
What you commit to
- Study type: Interventional
- Planned participants: 106
- From 1 Jul 2026 to the primary completion date, 1 Jan 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Other diagnosed oncological diseases over the past five years,
- Severe neurological impairment or other severe psychological/psychiatric diseases (depression, generalized anxiety disorder, psychosis-related disorders),
- Other uncontrolled/unstable diseases,
- Severe hearing and/or visual impairment,
Other
- Under psychotherapy or treatment for sexual problems,
- Participating concurrently in other clinical trials.
Who the study is looking for
- Prostate cancer survivors,
- 18 years old or older,
- Ability to give informed consent,
- Regular use of a smartphone and internet access.
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Faculdade de Psicologia e de Ciências da Educação da Universidade do Porto Coordinator of this site? Confirm its status | Porto | Portugal | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.